Cortexyme announces preclinical data demonstrating efficacy of COR803 for Covid infections
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Subscribe To Our Newsletter & Stay Updated